MedTrace Logo

SYMPLICITY HTN-3 Renal Denervation in Patients With Uncontrolled Hypertension

NCT01418261 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 535

Last updated 2017-04-26

No results posted yet for this study

Summary

The Symplicity HTN-3 study is a, multi-center, prospective, single-blind, randomized, controlled study of the safety and effectiveness of renal denervation in subjects with uncontrolled hypertension. Bilateral renal denervation will be performed using the Symplicity Catheter - a percutaneous system that delivers radiofrequency (RF)energy through the luminal surface of the renal artery.

Conditions

Interventions

DEVICE

Renal denervation (Symplicity Catheter System)

DIAGNOSTIC_TEST

Renal angiogram

Sponsors & Collaborators

  • Medtronic Vascular

    lead INDUSTRY

Principal Investigators

  • George Bakris, MD · Professor of Medicine, Hypertension Center Director University of Chicago Medical Center

  • Deepak L Bhatt, MD, MPH · VA Boston Healthcare System Department of Cardiology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2013-12-31
Completion
2017-02-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01418261 on ClinicalTrials.gov